COHANCE LIFESCIENCES LTD Stock Price Today (NSE: COHANCE)
Fundamental Score
COHANCE LIFESCIENCES LTD Share Price — Live NSE/BSE Price, Fundamentals & Analysis
COHANCE LIFESCIENCES LTD share price today is ₹301.45, down 1.13% on NSE/BSE as of 30 March 2026. COHANCE LIFESCIENCES LTD (COHANCE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹21.15K (Cr). The 52-week high for COHANCE share price is ₹1123.40 and the 52-week low is ₹266.70. At a P/E ratio of 61.57x, COHANCE is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.67% and a debt-to-equity ratio of 0.12.
COHANCE LIFESCIENCES LTD Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
COHANCE LIFESCIENCES LTD Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
COHANCE LIFESCIENCES Share Price: A Financial Analysis
One of the most compelling dynamics in the pharmaceutical sector is the ever-present pressure to innovate. Generic drug manufacturers, like COHANCE LIFESCIENCES LTD, often find themselves battling thin margins, requiring astute capital allocation and operational efficiency to maintain profitability and market share. This analysis delves into the financial standing of "COHANCE LIFESCIENCES share price," currently observed at ₹339.450012, focusing on its valuation metrics and performance relative to its peers.
COHANCE LIFESCIENCES LTD presents a Price-to-Earnings (PE) ratio of 61.57. This suggests that the market is currently valuing the company at a premium relative to its earnings per share. To contextualize this, consider
Mankind Pharma Ltd. A deeper dive would require assessing whether this premium is justified by anticipated future growth or reflecting qualitative factors such as perceived management quality. Is the leadership at COHANCE perceived as innovative and strategic when compared to leaders at Mankind Pharma, or are investors expecting something else? This comparison of management quality needs further investigation to understand the PE ratio better.The company's Return on Capital Employed (ROCE) stands at 14.89%. This metric indicates the efficiency with which COHANCE LIFESCIENCES LTD is using its capital to generate profits. A higher ROCE generally suggests a stronger competitive advantage, or "moat." The 14.89% ROCE can influence the company's ability to reinvest in its business, fund research and development, and potentially weather periods of economic downturn. This will allow them to continue innovating in the competitive pharmaceutical marketplace.
When compared to its sector peers, such as Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, further detailed financial benchmarking is needed to evaluate COHANCE LIFESCIENCES LTD's relative attractiveness. This includes analyzing their respective growth rates, profitability margins, and debt levels. The performance of COHANCE LIFESCIENCES share price should be viewed in the context of these broader industry trends and company-specific factors.
Disclaimer: This financial analysis of COHANCE LIFESCIENCES LTD is based on publicly available information and is intended for informational purposes only. It is a component of an 80-parameter fundamental audit verified by Sweta Mishra. It should not be interpreted as investment advice. No buy or sell recommendations are made.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
COHANCE LIFESCIENCES LTD Fundamental Analysis & Valuation Benchmarking
Educational evaluation of COHANCE across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (40.21%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Conservative Debt Levels (D/E: 0.12)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (14.48x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1137.04 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (57.49%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 27.32%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
7 factors identified
Premium Valuation Risk (P/E: 61.57x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-46.50%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-7.98%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-5.33% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-5.33% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
High Share Pledging Risk (100.00%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
COHANCE LIFESCIENCES LTD Financial Statements
Comprehensive financial data for COHANCE LIFESCIENCES LTD including income statement, balance sheet and cash flow
About COHANCE (COHANCE LIFESCIENCES LTD)
COHANCE LIFESCIENCES LTD is a dynamic pharmaceutical innovator, focused on the intricate dance between scientific discovery and efficient production. It navigates the complexities ...of drug development, specializing in the creation of building blocks for tomorrow's therapies. From initial research to large-scale manufacturing, the company is committed to precision and quality, serving as a trusted partner for pharmaceutical companies across the globe. COHANCE blends cutting-edge research with practical manufacturing expertise, playing a pivotal role in the intricate pharmaceutical supply chain. Its mission is to fuel advancements in healthcare by enabling the streamlined development and manufacturing of critical pharmaceutical components. COHANCE concentrates on the vital components that make medicines work, focusing on the development and manufacture of specialized chemical compounds. The company excels in the creation of Active Pharmaceutical Ingredients (APIs), the very heart of medications, along with advanced intermediates that serve as the stepping stones in their synthesis. COHANCE also manufactures specialty chemicals crucial for drug development, as well as formulated drugs that have proven their efficacy and are widely prescribed. By concentrating on core pharmaceutical elements, COHANCE empowers its clients to focus on innovation and distribution, confident in the quality and reliability of their source materials. COHANCE LIFESCIENCES LTD extends its reach beyond geographical boundaries, providing its specialized services and products to pharmaceutical companies in India, the United States, Europe, and other countries. COHANCE enables the quick and efficient development of life-saving pharmaceuticals by utilizing its worldwide network and state-of-the-art facilities. With a focus on quality control and regulatory compliance, COHANCE assures its clients that its products meet the highest standards. COHANCE is dedicated to advancing healthcare worldwide by providing vital components for the pharmaceutical sector with accuracy and dependability, from APIs and sophisticated intermediates to formulated drugs.
Company Details
Key Leadership
Corporate Events
COHANCE Share Price: Frequently Asked Questions
What is the current share price of COHANCE LIFESCIENCES LTD (COHANCE)?
As of 30 Mar 2026, 12:02 pm IST, COHANCE LIFESCIENCES LTD share price is ₹301.45. The COHANCE stock has a market capitalisation of ₹21.15K (Cr) on NSE/BSE.
Is COHANCE share price Overvalued or Undervalued?
COHANCE share price is currently trading at a P/E ratio of 61.57x, compared to the industry average of 31.77x. Based on this relative valuation, the COHANCE LIFESCIENCES LTD stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of COHANCE share price?
The 52-week high of COHANCE share price is ₹1123.40 and the 52-week low is ₹266.70. These values are updated daily from NSE/BSE price data.
What factors affect the COHANCE LIFESCIENCES LTD share price?
Key factors influencing COHANCE share price include quarterly earnings growth (Sales Growth: -7.98%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is COHANCE LIFESCIENCES LTD a good stock for long-term investment?
COHANCE LIFESCIENCES LTD shows a 5-year Profit Growth of -5.33% and an ROE of 12.67%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.12 before investing in COHANCE shares.
How does COHANCE LIFESCIENCES LTD compare with its industry peers?
COHANCE LIFESCIENCES LTD competes with major peers in the Pharmaceuticals. Investors should compare COHANCE share price P/E of 61.57x and ROE of 12.67% against the industry averages to determine competitive standing.
What is the P/E ratio of COHANCE and what does it mean?
COHANCE share price has a P/E ratio of 61.57x compared to the industry average of 31.77x. Investors pay ₹62 for every ₹1 of annual earnings.
How is COHANCE performing according to Bull Run's analysis?
COHANCE has a Bull Run fundamental score of 10.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does COHANCE belong to?
COHANCE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting COHANCE LIFESCIENCES LTD share price.
What is Return on Equity (ROE) and why is it important for COHANCE?
COHANCE has an ROE of 12.67%, which shows decent profitability but room for improvement. ROE measures how efficiently COHANCE LIFESCIENCES LTD generates profits from shareholders capital.
How is COHANCE debt-to-equity ratio and what does it indicate?
COHANCE has a debt-to-equity ratio of 0.12, which indicates conservative financing with low financial risk.
What is COHANCE dividend yield and is it a good dividend stock?
COHANCE offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in COHANCE LIFESCIENCES LTD shares.
How has COHANCE share price grown over the past 5 years?
COHANCE has achieved 5-year growth rates of: Sales Growth 7.51%, Profit Growth -5.33%, and EPS Growth -5.33%.
What is the promoter holding in COHANCE and why does it matter?
Promoters hold 57.49% of COHANCE shares, with 100.00% pledged. High promoter holding often indicates strong management confidence in COHANCE LIFESCIENCES LTD.
What is COHANCE market capitalisation category?
COHANCE has a market capitalisation of ₹21150 crores, placing it in the Large-cap category.
How volatile is COHANCE stock?
COHANCE has a beta of N/A. A beta > 1 suggests the COHANCE LIFESCIENCES LTD stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is COHANCE operating profit margin trend?
COHANCE has a 5-year average Operating Profit Margin (OPM) of 40.21%, indicating the company's operational efficiency.
How is COHANCE quarterly performance?
Recent quarterly performance shows COHANCE LIFESCIENCES LTD YoY Sales Growth of -7.98% and YoY Profit Growth of -46.50%.
What is the institutional holding pattern in COHANCE?
COHANCE has FII holding of 6.51% and DII holding of 20.81%. Significant institutional holding often suggests professional confidence in the COHANCE LIFESCIENCES LTD stock.